Comparative Pharmacology
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICYCLOMINE HYDROCHLORIDE versus PATHILON.
DICYCLOMINE HYDROCHLORIDE vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses in the gastrointestinal tract, leading to smooth muscle relaxation.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
10-20 mg orally 3-4 times daily
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
1.8 to 2.5 hours (terminal half-life, shorter in younger patients)
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Renal (∼79.5% as unchanged drug and metabolites) with minor biliary/fecal elimination (∼8-10%)
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category A/B
Category C
Anticholinergic
Anticholinergic